The R&D company and background of talquetamab-tgvs

Talquetamab is a new immunotherapy drug developed by the biopharmaceutical division of Johnson & Johnson, a world-renowned pharmaceutical company. The drug was developed to treat relapsed or refractory multiple myeloma (MM), a blood cancer caused by abnormal plasma cells, immune cells in the bone marrow. Multiple myeloma is often resistant to existing treatments, and the treatment process is complex and the recurrence rate is high. Therefore, the development of effective new drugs is particularly important.

Janssen Biotech, part of Johnson & Johnson, is committed to developing innovative medicines to meet the medical needs of patients around the world. As one of the world's leading pharmaceutical companies, Johnson & Johnson's biopharmaceutical division mainly focuses on drug research and development in the fields of cancer, immunology, neuroscience and infectious diseases. Tacquitumab is one of the company's important breakthroughs in the field of tumor immunotherapy. The drug is a targeted therapy drug that belongs to the class of antibody drug conjugates (ADC). It helps the patient's immune system recognize and destroy tumor cells by highly selectively targeting a specific receptor on multiple myeloma cells - GPRC5D.

The mechanism of action of Tacistumumab is based onGPRC5D receptor, which is a receptor highly expressed on the surface of multiple myeloma cells. By targeting this receptor, Talvey can precisely focus the immune system's killing effect on cancer cells, avoiding damage to normal cells. Therefore, the principle of action of this immunotherapy drug is more specific and has relatively fewer side effects than traditional chemotherapy.

Johnson & Johnson advanced the development of taquitutumab through its extensive global clinical trials network. Clinical trials of tasitumumab are primarily focused on treating patients with multiple myeloma who have received at least three lines of therapy and have relapsed. These patients are often resistant to existing treatments such as chemotherapy or immunotherapy and require more effective drugs to help control their disease.

Reference materials:https://go.drugbank.com/drugs/DB16678